Internal Medicine
The core lesson of the COVID-19 heart debate
22 Sep, 2020 | 10:00h | UTCThe Core Lesson of the COVID-19 Heart Debate – The Atlantic
Commentary on Twitter
https://twitter.com/ChecchiaPaul/status/1308065655099478018
Ensuring adequate palliative and hospice care during COVID-19 surges
22 Sep, 2020 | 09:57h | UTCEnsuring Adequate Palliative and Hospice Care During COVID-19 Surges – JAMA
Commentary on Twitter
An ethical approach to #pandemic surge planning requires providing for patients seeking symptom relief & comfort at the end of life. Not to do so undermines patient, family trust, emotional health, and core values of society https://t.co/P0LeYuZwzt @MatthewWynia @CUPallCare
— JAMA (@JAMA_current) September 22, 2020
Guideline: Management of dyslipidemia for cardiovascular disease risk reduction
22 Sep, 2020 | 09:33h | UTCSummary: VA/DoD Guidelines on Dyslipidemia Recommend Against Frequent LDL Testing – NEJM Journal Watch
Commentary on Twitter
https://twitter.com/ATallantMD/status/1308199038513278978
Editorial: Two remedies for inappropriate percutaneous coronary intervention—closing the gap between evidence and practice
22 Sep, 2020 | 09:28h | UTCEditorial: Two Remedies for Inappropriate Percutaneous Coronary Intervention—Closing the Gap Between Evidence and Practice (free for a limited period)
Original Studies: Potential Association of the ISCHEMIA Trial With the Appropriate Use Criteria Ratings for Percutaneous Coronary Intervention in Stable Ischemic Heart Disease – JAMA Internal Medicine (free for a limited period) AND US False Claims Act Investigations of Unnecessary Percutaneous Coronary Interventions – JAMA Internal Medicine (free for a limited period)
Clinical update: Hormonal contraception in women with hypertension
22 Sep, 2020 | 09:32h | UTCHormonal Contraception in Women With Hypertension – JAMA (free for a limited period)
Commentary on Twitter
https://twitter.com/JAMA_current/status/1308088618846691330
A comprehensive update on aspirin management during noncardiac surgery
22 Sep, 2020 | 09:24h | UTCA Comprehensive Update on Aspirin Management During Noncardiac Surgery – Anesthesia & Analgesia
[Preprint] Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: An international collaborative meta-analysis of randomized trials
20 Sep, 2020 | 21:42h | UTC
Commentary on Twitter
This meta-analysis of 7,913 patients from 26 RCTs (16 unpublished) found no mortality benefit to #hydroxychloroquine or chloroquine in COVID19
Combined summary OR for all-cause mortality for HCQ 1.08, 95%CI 0.99-1.18
Confirms HCQ does not help, may harmhttps://t.co/4o9bXkOo5Q pic.twitter.com/QG1XMzN0da
— Ilan Schwartz is on🦋 (@GermHunterMD) September 19, 2020
Decreased influenza activity during the COVID-19 pandemic
20 Sep, 2020 | 21:39h | UTCCommentary: COVID-19 prevention might translate into – MedicalXpress
Severe COVID-19 infections—knowledge gained and remaining questions
20 Sep, 2020 | 21:43h | UTCSevere COVID-19 Infections—Knowledge Gained and Remaining Questions – JAMA Internal Medicine
Commentary on Twitter
Just out @JAMAInternalMed – our editorial on what we've learned about severe #Covid19 pneumonia so far and what challenges are still ahead. Honored and proud to have written this together with Carolyn Calfee and Dan Brodie. https://t.co/rmVjUWNyvM
— Lieuwe Bos – Acute Pulmonary Medicine (@Acute_Pulmo_Med) September 18, 2020
Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19
20 Sep, 2020 | 21:30h | UTC
Editorial: Convalescent plasma for Covid-19
20 Sep, 2020 | 21:29h | UTCConvalescent plasma for covid-19 – The BMJ
Commentary on Twitter
Last month the US FDA authorised the emergency use of convalescent plasma for hospital patients with covid-19. What evidence underpinned the FDA’s controversial decision? And will the authorisation make it more difficult to recruit participants for RCTS? https://t.co/PMO13J2IOq
— The BMJ (@bmj_latest) September 19, 2020
Who gets a COVID vaccine first? Access plans are taking shape
20 Sep, 2020 | 21:24h | UTCWho gets a COVID vaccine first? Access plans are taking shape – Nature
Related: WHO Guidance: Allocation and prioritization of COVID-19 vaccination
Commentary on Twitter
Advisory groups around the world are working out plans for who should get priority access to a #covid19 vaccine: https://t.co/9g67rFJUrT pic.twitter.com/BLhAcKiVCK
— nature (@Nature) September 18, 2020
Hangover from alcohol boom could last long after pandemic ends
20 Sep, 2020 | 21:18h | UTCHangover From Alcohol Boom Could Last Long After Pandemic Ends – NPR
Commentary on Twitter
The alcohol industry has thrived during the #pandemic. But alcohol-related illnesses kill 88,000+ Americans every year—and the skyrocketing sales suggest a worrying reliance on alcohol to ease a stressful situation. https://t.co/8GIbAi9dM7
— Global Health NOW (@ghn_news) September 20, 2020
CDC Guidance: Indicators for dynamic school decision-making
18 Sep, 2020 | 09:45h | UTCIndicators for Dynamic School Decision-Making – Centers for Disease Control and Prevention
Commentary on Twitter
CDC releases new epi indicators and thresholds for risk of introduction and transmission of COVID-19 in schools https://t.co/jGQUV149Wt pic.twitter.com/xNmA7iUbaF
— Caitlin Rivers (@cmyeaton) September 16, 2020
Transmission of SARS-CoV-2: A review of viral, host, and environmental factors
18 Sep, 2020 | 09:43h | UTC
Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: A narrative review
18 Sep, 2020 | 09:39h | UTC
The pooled prevalence of pulmonary embolism in patients with COVID-19
18 Sep, 2020 | 09:37h | UTCThe pooled prevalence of pulmonary embolism in patients with COVID-19 – Intensive Care Medicine
Commentary on Twitter
Pulmonary embolism in #COVID19, be careful! quantitative meta-analysis ->
pooled prevalence in pts undergoing #PE diagnosis 28%
higher pooled prevalence in pts admitted to #ICU vs those admitted to non-ICU: 19 vs 9%
Open access @yourICM #COVIDFOAM #FOAMcc https://t.co/dUqKAVoeCV pic.twitter.com/fvmQnTlv1M— Intensive Care Medicine (@yourICM) September 15, 2020
Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong
18 Sep, 2020 | 09:34h | UTCClustering and superspreading potential of SARS-CoV-2 infections in Hong Kong – Nature Medicine
Commentary: Superspreaders of SARS-CoV-2 – Virology Blog
Commentaries on Twitter
Cases linked to #superspreading events are estimated to account for 80% of all local transmission of #SARSCoV2 in Hong Kong in a study with implications for public health policies. @bencowling88 @gmleunghku @SCauchemez @DillonCAdam @hkumed #quarantinehttps://t.co/tniPhKNhs5
— Nature Medicine (@NatureMedicine) September 17, 2020
We can learn a lot about superspreader events from this new @NatureMedicine paper https://t.co/ouO7CyGXQE by @DillonCAdam @bencowling88 @gmleunghku @hkumed
The Pareto 80/20 rule applied: 19% of infections were responsible for 80% of transmissions; 69% of cases did not transmit— Eric Topol (@EricTopol) September 17, 2020
Covid-19: Do many people have pre-existing immunity?
18 Sep, 2020 | 09:41h | UTCCovid-19: Do many people have pre-existing immunity? – The BMJ
Commentary on Twitter
It seemed a truth universally acknowledged that the human population had no pre-existing immunity to SARS-CoV-2, but is that actually the case? Peter Doshi explores the emerging research on immunological responseshttps://t.co/6LYRjxlWBQ
— The BMJ (@bmj_latest) September 17, 2020
ESC Position Paper: Integration of a palliative approach into heart failure care
18 Sep, 2020 | 09:24h | UTC
Commentary on Twitter
Palliative care should be part of every #heartfailure management programme. Read about how you can discuss and implement it in #EJHF https://t.co/lpR3Jb1I9p@MarcoMetra @HFA_President @kevin_damman pic.twitter.com/tA9nCMHiyS
— European Society of Cardiology Journals (@ESC_Journals) September 17, 2020
Study: Longer-than-necessary duration of outpatient antibiotic therapy for common outpatient infections
18 Sep, 2020 | 09:21h | UTC
Commentary on Twitter
NEW #CID using large NDTI dataset,clinicians defaulted 10d courses for most conditions, regardless of guideline-recommendations. Median antibiotic course
duration was 10 days for all conditions except acute cystitis. #IDTwitter https://t.co/WTJBFEcRtk pic.twitter.com/TAx7twUoTo— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) September 16, 2020
WHO Guidance: Allocation and prioritization of COVID-19 vaccination
17 Sep, 2020 | 09:42h | UTCCommentary: World Health Organization announces distribution plan for COVID-19 vaccine – ABD News
Related: An ethical framework for global vaccine allocation – Science
A case of probable Parkinson’s disease after SARS-CoV-2 infection
17 Sep, 2020 | 09:40h | UTCA case of probable Parkinson’s disease after SARS-CoV-2 infection – The Lancet Neurology
Commentary on Twitter
Parkinson's disease diagnosed after #SARSCoV2 in a 45 year-old-man https://t.co/SPLKDm1A2U @TheLancetNeuro
This has been reported with many other viruses but appears to be the 1st case with covid, very extensive workup pic.twitter.com/AtQfQXxjtm— Eric Topol (@EricTopol) September 17, 2020
How COVID-19 can damage the brain
17 Sep, 2020 | 09:36h | UTCHow COVID-19 can damage the brain – Nature
Commentary on Twitter
How COVID-19 can damage the brain https://t.co/uQUS5y9AXU 125 people in the United Kingdom with COVID-19 who had neurological or psychiatric effects. 62% had strokes and haemorrhages, and 31% had altered mental states, such as confusion or prolonged unconsciousness.
— Carlos del Rio (@CarlosdelRio7) September 16, 2020
Antimicrobial resistance: The next big pandemic?
18 Sep, 2020 | 09:19h | UTCAntimicrobial resistance: The next big pandemic? – Open Access Government